Not medical advice. Talk to your provider before using any peptide.
Full disclaimer
Amylin (IAPP)37 residuesKCNTATCATQRLANFLVHSSNNFGAILSSTNVGSNTYEach bubble = one amino acid. Size = residue mass. Color = chemical class.Also known as: IAPP, Islet Amyloid Polypeptide, Diabetes-Associated Peptide (DAP)
Over 90% of type 2 diabetes patients have IAPP amyloid deposits in their pancreatic islets at autopsy. Amylin, also called islet amyloid polypeptide (IAPP), is a 37-amino-acid hormone your beta cells co-secrete with every pulse of insulin. It slows gastric emptying, quiets glucagon after meals, and tells your brain you're full. The catch: native amylin misfolds into toxic fibrils at anything above physiological concentrations. That property ended its therapeutic prospects decades ago. Pramlintide (FDA-approved 2005) swapped three prolines to prevent aggregation. Cagrilintide extended the half-life to a full week. Native IAPP stays in the lab.
Thirty-seven amino acids, co-released with every pulse of insulin from your pancreatic beta cells. Amylin, formally islet amyloid polypeptide (IAPP, CAS 122384-88-7), was pulled from amyloid deposits in diabetic pancreatic tissue by Garth Cooper's group in 1987 [1]. Its job is straightforward: slow gastric emptying through vagal signaling, suppress postprandial glucagon from alpha cells, and tell your brain you're done eating via area postrema receptors. The problem is structural. Residues 20 through 29 of human IAPP form beta-sheet conformations that seed amyloid fibrils. At concentrations above normal physiology, monomers stack into oligomers, then protofibrils, then mature fibrils. The oligomeric intermediates punch holes in cell membranes, trigger ER stress, and activate the NLRP3 inflammasome. This process kills beta cells. It is the central pathology behind type 2 diabetes islet failure; Westermark and colleagues documented it across decades of autopsy work [2]. Nobody injects native IAPP therapeutically. Pramlintide (Symlin), FDA-approved in 2005, swaps three residues to prolines (A25P, S28P, S29P) and stops aggregation cold. Cagrilintide extends the half-life from 15 minutes to roughly seven days using fatty acid acylation. The CagriSema combination (cagrilintide plus semaglutide) produced 20.4% ITT weight loss at 68 weeks in REDEFINE 1 (NEJM 2025, 3,417 participants), with roughly 40% of participants losing 25% or more. Native amylin remains a research reagent for studying amyloid biology, beta-cell toxicity, and the structural parallels between IAPP and amyloid-beta in Alzheimer's disease.
Amylin binds heterodimeric receptor complexes: the calcitonin receptor (CTR) paired with one of three receptor activity-modifying proteins (RAMP1, RAMP2, or RAMP3). These combinations produce the AMY1, AMY2, and AMY3 receptor subtypes. Cross-reactivity at calcitonin gene-related peptide (CGRP) receptors also occurs, which matters for vascular research. Gastric emptying slows because amylin activates receptors in the area postrema, a circumventricular organ sitting outside the blood-brain barrier. That triggers vagal efferent signals inhibiting gastric motility and pyloric emptying. Nutrients reach the small intestine more gradually; the postprandial glucose curve flattens. Glucagon suppression works through both paracrine and central pathways acting on pancreatic alpha cells. The suppression is meal-specific. Amylin does not blunt the counter-regulatory glucagon response to hypoglycemia. That distinction is physiologically important and preserved in pramlintide. Satiety comes from area postrema and nucleus of the solitary tract activation. Ascending signals travel through the lateral parabrachial nucleus into the hypothalamus. This pathway is additive with GLP-1 receptor activation. CagriSema's REDEFINE 1 results confirmed that amylin plus GLP-1 outperformed either mechanism alone (20.4% ITT weight loss at 68 weeks, NEJM 2025). Then there is the aggregation pathway. The 20-29 residue segment starts as an intrinsically disordered region. Under high concentration, low pH, or membrane interaction, it adopts beta-sheet conformation. Monomers become oligomers, then protofibrils, then mature amyloid. The oligomeric intermediates are the most toxic species; they form pores in cell membranes through a mechanism resembling antimicrobial peptides [3].
Native amylin (IAPP) has well-characterized physiology: slows gastric emptying, suppresses postprandial glucagon, promotes satiety. Amyloidogenic tendency makes SC dosing dose-unpredictable; all clinical-stage development uses non-aggregating analogs. Amylin-class compounds show significant weight loss: cagrilintide + semaglutide (CagriSema) achieved 20.4% ITT body weight reduction in REDEFINE 1 (NEJM 2025). Native IAPP is restricted to research.
REDEFINE 1: CagriSema Phase 3 (NEJM 2025, DOI 10.1056/NEJMoa2502081): 20.4% ITT weight loss, 22.7% per-protocol, 40.4% achieved ≥25% loss at 68 weeks; pramlintide FDA approval 2005 (Symlin) as direct non-amyloidogenic amylin analog
No human clinical trials with native IAPP; aggregation makes effective delivered dose unpredictable (aggregated IAPP is inactive at receptors); 13-min half-life lower bound is rat IV bolus data (human ~19–20 min per Larsson 1998, PMID 9612249); dose-response is non-linear due to concentration-dependent oligomerization
No documented self-experimentation with native amylin (IAPP 1-37). Community amylin-class data comes entirely from pramlintide (diabetic users on r/diabetes) and emerging gray-market cagrilintide biohackers. Native IAPP is impractical outside lab conditions due to aggregation.
No community self-experimentation exists with native IAPP. Science is strong for amylin-class mechanisms (pramlintide FDA-approved 2005; CagriSema Phase 3 complete 2025) but all human data comes from analogs engineered to avoid aggregation. Native IAPP remains a research reagent only.
| Level | Dose / Injection | Frequency |
|---|---|---|
| Beginner | 10mcg | 3x Daily |
| Moderate | 25mcg | 3x Daily |
| Aggressive | 50mcg | 3x Daily |
This is a research reagent, not a therapeutic peptide. If you're looking for amylin replacement therapy, pramlintide (Symlin) is the FDA-approved option with three proline swaps that stop aggregation. Reconstitution math for a 1 mg vial: add 2 mL acidic buffer (pH 3 to 4). That gives you 500 mcg/mL. At 10 mcg per dose, each injection is 0.02 mL, which is 2 units on a U-100 insulin syringe. At 25 mcg, it is 5 units. At 50 mcg, it is 10 units. For a 5 mg vial with 2 mL, you get 2,500 mcg/mL; 50 mcg would be 0.02 mL (2 units). Use the 1 mg vial for research dosing accuracy. The thing most beginners miss: you cannot reconstitute native IAPP in standard bacteriostatic water at neutral pH. Aggregation begins within hours. You need acidic buffer (pH 3 to 4), or HFIP pre-treatment. Dissolve in hexafluoroisopropanol, lyophilize into aliquots, reconstitute fresh. Prepare only the volume you need right before use. Discard anything with haziness or particulates; that is aggregated IAPP, and it is both inactive and cytotoxic.
Not applicable: amylin (IAPP) is a research-only peptide without established clinical cycling protocols. For the therapeutic analog pramlintide, continuous daily dosing is used. For research applications, native amylin is typically used in acute experiments rather than chronic dosing schedules due to its aggregation tendency.
No cycling protocol exists for native amylin. It is a research reagent used in acute experiments, not a therapeutic agent. The FDA-approved analog pramlintide is dosed continuously without cycling. The next-generation analog cagrilintide is dosed continuously (once weekly). Aggregation tendency makes sustained chronic SC administration impractical outside controlled research settings.
Or use the universal Peptide Calculator for any peptide.
Expected: Gastric emptying delay within 15–30 min; postprandial glucagon suppression; satiety signaling via area postrema. Effects limited by ~15–20 min half-life.
Monitor: Blood glucose before and 2 hours post-injection. Injection site inspection for induration. Renal function baseline recommended.
Let it reach room temperature (5 to 10 minutes).
Prepare acidic reconstitution buffer (sterile water adjusted to pH 3 to 4). Do not use standard bacteriostatic water at neutral pH.
Swirl gently until dissolved. Do not shake. This gives you 500 mcg/mL.
Draw your dose with a U-100 insulin syringe (29 to 31 gauge). For 10 mcg, draw 2 units. For 25 mcg, draw 5 units. For 50 mcg, draw 10 units.
Rotate injection sites every dose; repeated injection at the same spot raises local amyloid deposition risk.
Check blood glucose before injection and again 2 hours after. Have fast-acting glucose within arm's reach.
Reconstituted native IAPP must be used within 24 hours. Discard remaining solution the next day.
Before each subsequent draw, inspect the vial against a light source. Any cloudiness or visible particulates means aggregation has occurred. Discard the entire vial.
Faster onset; same dose range but higher systemic exposure (bypasses SC aggregation at injection site); continuous infusion required to maintain steady-state due to 15–20 min half-life
Continuous IV infusion protocol used in the Larsson et al. 1998 human PK study (PMID 9612249): the primary source for human half-life data. IV bolus carries hypotension risk. Emergency vasopressor support must be available.
Not established for metabolic applications
Intranasal amylin studied in CNS/Alzheimer's research context (preclinical only); no human protocols available. CNS delivery rationale: bypasses blood-brain barrier for direct amyloid seeding studies.
FDA-approved non-amyloidogenic amylin analog (3× Pro substitutions: A25P, S28P, S29P). Pramlintide + insulin is the validated clinical approach: pramlintide is the therapeutic replacement for native IAPP, not a complement to it.
Pramlintide 15–120 mcg TID SC (pre-meal) + concurrent insulin with 50% dose reduction at initiation per FDA label
Long-acting acylated amylin analog (t½ ~7 days). CagriSema (cagrilintide + semaglutide) achieved 20.4% ITT weight loss in REDEFINE 1 (NEJM 2025). Demonstrates amylin + GLP-1 additive mechanism. Not a native IAPP combination.
Cagrilintide 2.4 mg QW SC + semaglutide 2.4 mg QW SC (REDEFINE 1 Phase 3 protocol, 68 weeks)
GLP-1 receptor agonist with complementary mechanism to amylin class (gastric emptying + central satiety additive). Off-label pramlintide + semaglutide case reports exist (PMID-linked JCEM Case Rep 2023). Native IAPP has no documented stacks with semaglutide.
Amylin receptor agonism activates the classical renin-angiotensin system (RAS): PMID 41207308 (Muskiet et al., Lancet Nov 2025). RAS-active drugs may interact, though the same paper proposes ACE-i/ARBs co-administered with amylin may redirect toward the protective Ang-1-7/Mas axis. Mechanistic uncertainty warrants caution and monitoring; not an absolute contraindication but flag for clinical context.
Amylin is cleared renally via insulin-degrading enzyme (IDE) and neprilysin. Nephrotoxic agents (NSAIDs, aminoglycosides, contrast agents) impair clearance, elevating plasma amylin levels and amyloid deposition risk. Renal impairment is an explicit contraindication for pramlintide per prescribing information.
Amylin potentiates insulin's hypoglycemic effect via gastric emptying delay (slowing glucose absorption) and postprandial glucagon suppression. Pramlintide requires a mandatory 50% insulin dose reduction at initiation (black-box warning). Native amylin carries equivalent or greater risk.
Do not combineThe biggest concern with native amylin is amyloid toxicity. At concentrations above normal physiology, IAPP self-assembles into oligomers and fibrils that are directly cytotoxic to pancreatic beta cells. Aggregated IAPP disrupts cell membranes, triggers ER stress, activates the NLRP3 inflammasome, and induces apoptosis [3]. This is not a theoretical risk. It is the central pathological process behind type 2 diabetes islet destruction, confirmed across decades of autopsy studies showing IAPP-derived amyloid in over 90% of T2D patients (Westermark et al., Physiol Rev 2011)[2]. Repeated subcutaneous injection of native IAPP in preclinical models has produced local amyloid deposits at injection sites. These nodules are not reversible. The effective delivered dose becomes unpredictable because aggregated peptide is inactive at amylin receptors (AMY1-3) but still toxic to surrounding tissue. Without thioflavin T fluorescence testing, you cannot confirm whether the solution in your syringe is monomeric or aggregated. Nausea is the most common acute effect at any dose. It is area postrema-mediated, the same mechanism behind pramlintide's GI side effects. With pramlintide, nausea peaks in weeks one through three and typically attenuates. Expect similar kinetics with native IAPP, though data is limited to preclinical observations. Hypoglycemia is possible whenever amylin is combined with insulin or insulin secretagogues. Amylin delays gastric emptying (slowing glucose absorption) and suppresses glucagon (removing a counter-regulatory buffer). The pramlintide prescribing information carries a black-box warning requiring a 50% insulin dose reduction at initiation. Native amylin carries equivalent or greater risk because the effective dose is unpredictable. Injection site reactions (pain, erythema) occur with subcutaneous administration. Unlike typical injection site reactions, any persistent nodule at a native IAPP injection site warrants concern for local amyloid deposition. No human safety data exists for native IAPP administration. All clinical side effect data comes from the pramlintide analog. Pregnant or breastfeeding individuals should have zero exposure. Anyone with gastroparesis or severe GI motility disorders should avoid amylin-class compounds entirely, as the gastric emptying delay compounds existing motility dysfunction. When to stop: injection site nodules or induration, visible turbidity in reconstituted solution, hypoglycemia unawareness symptoms, or intolerable GI effects.
Verify Amylin (IAPP) dosing and safety with a second opinion
Native IAPP aggregates spontaneously in solution: aggregated oligomers and fibrils are both inactive at amylin receptors and cytotoxic to beta cells. Effective delivered dose is fundamentally unpredictable without aggregation-state testing. No GMP standards apply to research-grade IAPP. The same physicochemical property (amyloidogenicity) that limits this compound clinically also makes research-grade quality assessment critical.
| Test | When | Target |
|---|---|---|
| Blood glucose | Before each injection and 2 hours post-injection during research protocols | Maintain 70–180 mg/dL; treat <70 mg/dL with fast-acting glucose immediately |
| Serum creatinine / eGFR | Baseline; repeat every 2–4 weeks during any chronic research protocol | eGFR >60 mL/min/1.73m²: reassess protocol if below this threshold |
| Injection site inspection | Before each injection; document site rotation | — |
| Thioflavin T fluorescence (solution QC: in vitro) | Each batch of reconstituted peptide before use | — |
Amylin potentiates hypoglycemia via gastric emptying delay and glucagon suppression; mandatory with concurrent insulin or secretagogues
Amylin is renally cleared via IDE and neprilysin; impaired renal function elevates plasma amylin levels and amyloid deposition risk; pramlintide contraindicated in renal impairment
Repeated SC injection of native IAPP can produce local amyloid deposits (induration, nodules): documented in preclinical models; rotate sites to minimize focal concentration
Confirms monomeric vs aggregated state of the peptide solution; ThT fluorescence increase (>2× baseline) indicates amyloid formation: discard and reconstitute fresh
In research settings, subcutaneous amylin produces rapid physiological effects: gastric emptying slows within 15-30 minutes, postprandial glucagon is suppressed, and satiety signaling increases. Effects parallel those of pramlintide but with shorter duration due to the ~15-minute half-life. Nausea may occur at higher doses.
Repeated dosing in preclinical models shows consistent postprandial glucose reduction and food intake suppression. Aggregation at injection sites may occur with repeated subcutaneous administration: a limitation not seen with pramlintide.
In chronic preclinical studies, amylin-treated animals show reduced weight gain and improved glucose tolerance. However, local amyloid deposition at injection sites has been observed in some models, underscoring why native amylin was replaced by pramlintide for therapeutic use.
At 25-50 micromolar concentrations in neutral buffer, native amylin shows a characteristic sigmoidal aggregation curve: a lag phase of 2-8 hours (nucleation), a rapid growth phase of 4-12 hours (fibril elongation), and a plateau by 24-48 hours (mature fibrils). Thioflavin T fluorescence and electron microscopy are standard monitoring methods.
0 to 30 minutes (per injection): Effects hit fast. Gastric emptying slows within 15 to 30 minutes. Postprandial glucagon drops roughly 50% from baseline. Satiety signaling through the area postrema and hypothalamus kicks in at the same window. Everything fades quickly; the half-life sits around 13 to 22 minutes in humans (Larsson et al. 1998, tracked clearance at about 19 to 20 minutes)[4]. Pramlintide proxy data from r/diabetes: nausea shows up at 15 to 30 minutes, appetite drops noticeably, and meal portions shrink. Days 1 through 7: Preclinical models show consistent postprandial glucose reduction with freshly prepared peptide across a week of dosing. Injection site amyloid deposition becomes a real concern with repeated subcutaneous administration at the same spot. Pramlintide users on r/diabetes report nausea peaking around days one through three. It starts fading by day seven with consistent three-times-daily use. Weeks 2 through 4 (preclinical models only): Animal data shows reduced weight gain and improved glucose tolerance over this window. Local amyloid nodules at injection sites are documented in several preclinical papers. This finding locked native amylin out of therapeutic development permanently. No human data exists at this duration. 68 weeks, amylin analog class benchmark (REDEFINE 1, 2025): CagriSema delivered 20.4% ITT body weight reduction, 22.7% per-protocol, with roughly 40% of participants clearing 25% or greater loss. REDEFINE 2 (type 2 diabetes population) came in at 13.7% ITT. Native IAPP cannot replicate these outcomes. The 15-minute half-life versus cagrilintide's seven-day half-life and the aggregation problem make comparison meaningless. Gray-market cagrilintide reports from r/Retatrutide and r/Biohackers confirm early weight loss when stacked with semaglutide, but systematic community data is limited.
Gastric emptying slows within 15–30 min; postprandial glucagon suppressed by ~50% vs baseline; satiety signaling via area postrema and hypothalamus activated. Duration of effect limited by ~15–20 min half-life (human; rat data ~13 min).
No human self-experiment data for native IAPP. Pramlintide proxy (r/diabetes): nausea onset at 15–30 min; reduced appetite and smaller meal sizes reported consistently.
Consistent postprandial glucose reduction in preclinical models with freshly prepared peptide. Injection site amyloid deposition possible with repeated SC at the same site, especially at higher doses.
No data for native IAPP. Pramlintide proxy: nausea typically peaks days 1–3 and begins attenuating by day 7 with consistent TID use.
Reduced weight gain and improved glucose tolerance in animal models. Local amyloid deposition at SC injection sites documented in several preclinical studies: the primary reason native amylin was replaced by pramlintide for any therapeutic application.
No data available for native IAPP
CagriSema: 20.4% ITT body weight reduction; 22.7% per-protocol; 40.4% of participants achieved ≥25% loss. REDEFINE 2 (T2D): 13.7% ITT. Significant systolic BP reductions observed. Native IAPP cannot replicate these outcomes due to half-life (15 min vs 7 days) and aggregation.
Gray-market cagrilintide biohackers report early weight loss results stacked with semaglutide; limited systematic community data available.
Source: Native human amylin has a plasma half-life of approximately 13-22 minutes (~15 min average) due to rapid renal clearance and enzymatic degradation by insulin-degrading enzyme (IDE) and neprilysin.
Loading the interactive decay curve.
Amylin (IAPP) is classified as a research-only peptide. It has no FDA approval for any therapeutic indication. The FDA-approved amylin analog is pramlintide (Symlin), approved in 2005 as adjunctive therapy for insulin-treated type 1 and type 2 diabetes. Native amylin is available from peptide synthesis vendors (AnaSpec, Bachem, Biosynth) for research applications. It is not sold as a pharmaceutical product and carries no GMP manufacturing standards. Compounding pharmacies do not formulate native IAPP. Cagrilintide, the next-generation long-acting amylin analog from Novo Nordisk, is in late-stage clinical development (CagriSema Phase 3 complete, REDEFINE program). Not yet FDA-approved. WADA status: amylin and its analogs are not listed on the WADA prohibited substance list. This content is for educational and research reference only. Native amylin is not for human therapeutic use. Consult a qualified healthcare provider for any amylin-class therapy.
Peptide Schedule Research TeamReviewed Apr 20269 Citations
